Cargando…

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Joycelyn J. X., Chan, Jack J., Choo, Su Pin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548260/ https://www.ncbi.nlm.nih.gov/pubmed/28943627 http://dx.doi.org/10.3390/diseases3040306

Ejemplares similares

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
por: Bouattour, Mohamed, et al.
Publicado: (2018)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

Targeted Therapy in Hepatocellular Carcinoma
por: Chua, Clarinda W. L., et al.
Publicado: (2011)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
por: Hu, Chi-Tan, et al.
Publicado: (2017)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met(+) Hepatocellular Carcinoma
por: Steinway, Steven N., et al.
Publicado: (2015)

Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
por: García-Vilas, Javier A, et al.
Publicado: (2018)

ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
por: Ma, Xiao-Lu, et al.
Publicado: (2023)

c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo
por: Huang, Xiaochen, et al.
Publicado: (2022)

Epigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma
por: Ogunwobi, Olorunseun O., et al.
Publicado: (2013)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET(+) hepatocellular carcinoma
por: Gao, Shan, et al.
Publicado: (2022)

Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
por: Lee, J.J.X., et al.
Publicado: (2021)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
por: Qin, Shukui, et al.
Publicado: (2019)

Induction of tumor initiation is dependent on CD44s in c-Met(+) hepatocellular carcinoma
por: Dang, Hien, et al.
Publicado: (2015)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan
por: Yau, Thomas, et al.
Publicado: (2022)

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
por: Xu, Zhong, et al.
Publicado: (2018)

Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific Region: A Review and Multidisciplinary Expert Opinion
por: Ogasawara, Sadahisa, et al.
Publicado: (2021)

Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway
por: Li, Ming, et al.
Publicado: (2017)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Anti-neoplastic Effect of Ginkgolide C through Modulating c-Met Phosphorylation in Hepatocellular Carcinoma Cells
por: Yang, Min Hee, et al.
Publicado: (2020)

Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Han, Peng, et al.
Publicado: (2017)

Development of antibody-based c-Met inhibitors for targeted cancer therapy
por: Lee, Dongheon, et al.
Publicado: (2015)

Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
por: Liu, Yuchen, et al.
Publicado: (2020)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth
por: Luo, Teng, et al.
Publicado: (2019)

c-Met expression in renal cell carcinoma with bone metastases
por: Silva Paiva, Rita, et al.
Publicado: (2020)

The clinical and functional significance of c-Met in breast cancer: a review
por: Ho-Yen, Colan M, et al.
Publicado: (2015)

The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid
por: Ruco, Luigi, et al.
Publicado: (2014)

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2009)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma
por: Wu, Ju-gang, et al.
Publicado: (2014)

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
por: Jafarnejad, Mohammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q7nb7pejunb3cavgd87knurgvf